SNY
Strong BuyFull HouseAI screen passSanofi · Healthcare · France · $99.8B
$40.20 +1.6% · close 7 Oct · scored 9 Oct
Full House: Strong business, sensible price, market agrees. The rare full house.
Read our full research report on SNY (Jun 2026), freeAs of 9 Oct 2026, MoatMap's StockRank for Sanofi (SNY) is 93/100: Quality 64, Value 79, Momentum 52, ranked against 24,000+ stocks in 35 markets.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Passes the eligibility threshold with all three legs (Quality 66, Value 76, Momentum 61) above 60. No adverse in-house signals or negative EPS revisions were identified, supporting a screen-pass.
ABOUT SANOFI
Read
Sanofi is a global biopharmaceutical company engaged in the research, development, manufacturing, and marketing of a broad range of healthcare solutions, encompassing prescription drugs, vaccines, and consumer healthcare products. Its significant competitive moat stems from a highly diversified portfolio of patented drugs and vaccines, strong global R&D capabilities, and extensive commercial reach across multiple therapeutic areas. Sanofi is a leading multinational pharmaceutical firm, particularly prominent in vaccine production and innovation in rare diseases and immunology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.5B | 46.7B | 49.6B | 52.4B | 4.8% | 55.1B | 57.2B | 60.8B | 7.7% |
| EPS | 3.01 | 2.42 | 2.57 | 3.59 | 6.0% | 1.83 | 3.85 | 4.15 | 7.5% |
| Shares | 1.3B | 1.3B | 1.3B | 1.2B | -4.2% | — | — | — | — |
| Debt | 23.8B | 20.7B | 20.1B | 22.8B | -1.4% | 26.5B | — | — | — |
| Equity | 83.8B | 83.0B | 86.9B | 80.0B | -1.5% | — | — | — | — |
| Op CF | 11.8B | 11.5B | 10.2B | 12.1B | 0.7% | 13.3B | — | — | — |
| Inv CF | -2.3B | -7.0B | -4.9B | -2.7B | — | — | — | — | — |
| Fin CF | -6.5B | -9.0B | -6.5B | -9.2B | — | — | — | — | — |
No clear trend: not near its 52-week low, and not in a steady uptrend.
Calmer than 87% of stocks we rank over the past year (22% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SNY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SNY | Sanofi(you) | $99.8B | 93 | Strong Buy |
| G1SK34.SA | GSK plc | $99.9B | 90 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $124.9B | 98 | Strong Buy |
| NVON.MX | Novo Nordisk A/S | $168.7B | 95 | Strong Buy |
| PFE | Pfizer Inc. | $160.6B | 90 | Strong Buy |
| AMGN | Amgen Inc. | $219.5B | 91 | Strong Buy |
| 4578.T | Otsuka Holdings Co., Ltd. | $36.6B | 92 | Strong Buy |
| NOVN.SW | Novartis AG | $271.2B | 88 | Strong Buy |
| GILD | Gilead Sciences, Inc. | $187.7B | 78 | Buy |
| ROP.SW | Roche Holding AG | $351.1B | 88 | Strong Buy |
Peer medians: ROE 2.5% · P/E 23.6x · Gross margin 53.4%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.